Dr. Reddy's (RDY) partners with Shanghai Henlius Biotech to develop and market biosimilar versions of J&J's (JNJ) multiple ...

Dr Reddy's Laboratories has signed a licence agreement with Shanghai Henlius Biotech to develop and commercialise HLX15, a ...

What Does the Darzalex Faspro Market Look Like? The darzalex faspro market witnessed significant growth in recent years with recorded XX in historic compound annual growth rate HCAGR. Within a ...

HLX15 is being developed as a biosimilar of Darzalex® & Darzalex Faspro®*, which are indicated for the treatment of multiple myeloma. The agreement combines Dr. Reddy’s global commercial ...

Dr Reddy’s inks pact with Henlius to commercialize HLX1, a biosimilar candidate in US & Europe: Our Bureau, Bengaluru Thursday, February 6, 2025, 17:20 Hrs [IST] Dr Reddy’s La ...

sold under the tradename DARZALEX FASPRO ® in the U.S.), as reported by J&J were USD 11,670 million in 2024. Net trade sales were USD 6,588 million in the U.S. and USD 5,082 million in the rest of the ...

Global net sales of EPKINLY/TEPKINLY were USD 281 million in 2024. Net product sales in the U.S. and Japan by Genmab were DKK 1,743 million in 2024 compared to DKK 421 million in 2023. EPKINLY was ...

sold under the tradename DARZALEX FASPRO ® in the U.S.), as reported by J&J were USD 11,670 million in 2024. Net trade sales were USD 6,588 million in the U.S. and USD 5,082 million in the rest ...

Genmab is an international biotechnology company with a core purpose of guiding its unstoppable team to strive toward improving the lives of patients with innovative and differentiated antibody ...